Statements (63)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:legal_case
|
gptkbp:appeals_to |
patent infringement
|
gptkbp:area |
patent law
|
gptkbp:case_analysis |
research and development
legal scholars biotech innovation legal commentary legal forums future litigation patent law evolution impact on stakeholders |
gptkbp:case_number |
court records
litigation history legal overview 2019-1140 |
gptkbp:case_outcome |
gptkb:healthcare_access
gptkb:majority_opinion industry standards market competition investment strategies legal certainty market dynamics regulatory environment drug pricing monetary damages legal reviews innovation landscape biotech sector affirmed lower court biotech funding patent clarity |
gptkbp:case_significance |
intellectual property rights
|
gptkbp:clinical_trial |
gptkb:court_cases
|
gptkbp:consequences |
patent enforcement
|
gptkbp:court |
gptkb:United_States_Court_of_Appeals_for_the_Federal_Circuit
|
gptkbp:decided_by |
gptkb:2023
en banc |
gptkbp:dissenting_opinion |
dissenting judges
|
gptkbp:duration |
9 years
|
https://www.w3.org/2000/01/rdf-schema#label |
Amgen Inc. v. Sanofi
|
gptkbp:impact |
innovation in drug development
|
gptkbp:involves |
gptkb:Sanofi
gptkb:Amgen_Inc. |
gptkbp:is_cited_in |
2023 WL 1234567
|
gptkbp:jurisdiction |
gptkb:United_States
|
gptkbp:legal_issue |
written description
|
gptkbp:legal_outcome |
patent upheld
|
gptkbp:legal_principle |
litigation tactics
enablement |
gptkbp:legal_representation |
law firms
|
gptkbp:legislation |
Patent Act
|
gptkbp:outcome |
biopharmaceutical patents
patent validity |
gptkbp:party |
gptkb:court_cases
|
gptkbp:precedent |
biotechnology patents
future patent cases |
gptkbp:publication_year |
gptkb:2014
|
gptkbp:related_cases |
gptkb:Amgen_Inc._v._Sandoz_Inc.
|
gptkbp:related_to |
biologics
|
gptkbp:significance |
impact on pharmaceutical industry
|
gptkbp:witnesses |
scientific evidence
|
gptkbp:bfsParent |
gptkb:United_States_Court_of_Appeals_for_the_Federal_Circuit
|
gptkbp:bfsLayer |
5
|